share_log

These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt In A Risky Way

These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt In A Risky Way

這4項措施表明舒宇民用藥店(SZSE:301017)正在冒險地使用債務。
Simply Wall St ·  06/19 23:33

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. Importantly, ShuYu Civilian Pharmacy Corp., Ltd. (SZSE:301017) does carry debt. But should shareholders be worried about its use of debt?

David Iben曾經說過:'波動率並非我們所關心的風險。我們關心的是避免永久性的資本損失。' 當你分析一個企業的風險時,考慮它的資產負債表是很自然的,因爲債務經常是一個企業崩潰的原因。重要的是,深圳市舒昱民用藥有限公司(SZSE:301017)確實負債。但股東們應該擔心它的債務使用嗎?

When Is Debt A Problem?

什麼時候負債才是一個問題?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

債務是幫助企業成長的工具,但如果企業無法償還債務,那麼它存在於債權人的威脅之下。如果情況變得非常糟糕,債權人可以接管企業。然而,更經常發生的(但仍然成本高昂)是企業必須以低價發行股份,永久性地稀釋股東,以加強其資產負債表。然而,通過取代稀釋,債務可以成爲那些需要資本以高回報率投資於增長的企業的極好工具。在考慮企業使用多少債務時,首先要做的是將其現金和債務合併到一起。

How Much Debt Does ShuYu Civilian Pharmacy Carry?

深圳市舒昱民用藥承擔了多少債務?

As you can see below, at the end of March 2024, ShuYu Civilian Pharmacy had CN¥3.60b of debt, up from CN¥2.47b a year ago. Click the image for more detail. However, because it has a cash reserve of CN¥1.58b, its net debt is less, at about CN¥2.01b.

正如您在下面看到的,截至2024年3月底,深圳市舒昱民用藥負債達36億人民幣,高於一年前的24.7億人民幣。點擊圖片查看更多細節。但由於其擁有現金儲備15.8億人民幣,淨債款較少,約爲20.1億人民幣。

debt-equity-history-analysis
SZSE:301017 Debt to Equity History June 20th 2024
SZSE:301017資產負債歷史6月20日, 2024

How Strong Is ShuYu Civilian Pharmacy's Balance Sheet?

深圳市舒昱民用藥的財務狀況如何?

We can see from the most recent balance sheet that ShuYu Civilian Pharmacy had liabilities of CN¥5.35b falling due within a year, and liabilities of CN¥1.85b due beyond that. Offsetting this, it had CN¥1.58b in cash and CN¥1.46b in receivables that were due within 12 months. So its liabilities total CN¥4.16b more than the combination of its cash and short-term receivables.

從最近的資產負債表可以看出,深圳市舒昱民用藥的短期到期債務爲53.5億人民幣,長期到期債務爲18.5億人民幣。抵消這一點的是,它有現金15.8億人民幣和應收賬款14.6億人民幣,在12個月內到期。因此,它的負債總額比其現金和短期應收賬款的組合高出41.6億人民幣。

This is a mountain of leverage relative to its market capitalization of CN¥4.28b. This suggests shareholders would be heavily diluted if the company needed to shore up its balance sheet in a hurry.

相對於其市值42.8億人民幣,這是一座債務山。這意味着如果公司需要迅速支援其資產負債表,股東將被嚴重稀釋。

We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.

Service Corporation International的債務是其EBITDA的3.5倍,而其EBIT可覆蓋其利息開支的3.7倍。綜合考慮,雖然我們不希望看到債務水平上升,但我們認爲它可以應對當前的槓桿。好消息是,Service Corporation International在過去12個月中將其EBIT提高了2.9%,從而逐漸降低了其相對於收益的債務水平。毫無疑問,我們從資產負債表中獲得了有關債務的大部分內容。但是,相對於資產負債表,更重要的是未來收益,這將決定Service Corporation International維持健康資產負債表的能力。如果您關注未來,您可以查看此免費報告,其中有分析師的利潤預測。

Weak interest cover of 2.2 times and a disturbingly high net debt to EBITDA ratio of 6.7 hit our confidence in ShuYu Civilian Pharmacy like a one-two punch to the gut. This means we'd consider it to have a heavy debt load. Worse, ShuYu Civilian Pharmacy's EBIT was down 42% over the last year. If earnings continue to follow that trajectory, paying off that debt load will be harder than convincing us to run a marathon in the rain. When analysing debt levels, the balance sheet is the obvious place to start. But it is ShuYu Civilian Pharmacy's earnings that will influence how the balance sheet holds up in the future. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

弱的2.2倍利息覆蓋率和驚人的6.7倍淨債務與稅前利潤比率如同重擊我們信懇智能的肚子。這意味着我們認爲它有重債負荷。更糟糕的是,舒昱民用藥的稅前利潤去年下降了42%。如果收益繼續沿着那條軌跡,償還那筆債務將比說服我們在雨中跑馬拉松更困難。當分析債務水平時,資產負債表顯然是開始的地方。但是,深圳市舒昱民用藥的收益將影響未來資產負債表的持久性。因此,在考慮債務時, definitely值得關注收益趨勢。點擊此處,了解互動快照。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. In the last three years, ShuYu Civilian Pharmacy created free cash flow amounting to 8.1% of its EBIT, an uninspiring performance. That limp level of cash conversion undermines its ability to manage and pay down debt.

但我們的最後一考慮也很重要,因爲一家公司不能用虛假收益支付債務;它需要有真金白銀。因此,值得檢查有多少稅前利潤是由自由現金流支持的。在過去的三年中,舒昱民用藥創造的自由現金流相當於其稅前利潤的8.1%,表現不太好。 這種虛弱的現金轉化水平削弱了其管理和償還債務的能力。

Our View

我們的觀點

On the face of it, ShuYu Civilian Pharmacy's net debt to EBITDA left us tentative about the stock, and its EBIT growth rate was no more enticing than the one empty restaurant on the busiest night of the year. And furthermore, its conversion of EBIT to free cash flow also fails to instill confidence. Taking into account all the aforementioned factors, it looks like ShuYu Civilian Pharmacy has too much debt. That sort of riskiness is ok for some, but it certainly doesn't float our boat. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. Be aware that ShuYu Civilian Pharmacy is showing 3 warning signs in our investment analysis , and 1 of those is significant...

乍一看,舒宇平民藥店的淨債務/EBITDA令我們對該股持保留態度,其EBIT增長率也不比一年中最繁忙的夜晚空蕩蕩的餐廳更吸引人。此外,它將EBIT轉化爲自由現金流的能力也未能增強我們的信心。考慮到所有上述因素,舒宇平民藥店的債務過多,這種風險對某些人來說可能沒有問題,但肯定不能打動我們。當分析債務水平時,資產負債表是開始的明顯地方,但最終,每個公司都可能存在超出資產負債表範圍的風險。請注意,舒宇平民藥店正在我們的投資分析中顯示3個警示信號,其中1個具有重要意義......

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

當然,如果您是那種喜歡購買沒有負債負擔的股票的投資者,則今天就可以發現我們的獨家淨現金增長股清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論